MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Inmode Ltd

Chiusa

SettoreSettore sanitario

14.06 -0.21

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.95

Massimo

14.15

Metriche Chiave

By Trading Economics

Entrata

-4.9M

22M

Vendite

-2.4M

93M

P/E

Media del settore

6.702

89.037

EPS

0.38

Margine di Profitto

23.467

Dipendenti

599

EBITDA

-5.4M

26M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+22.73% upside

Dividendi

By Dow Jones

Utili prossimi

10 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

18M

946M

Apertura precedente

14.27

Chiusura precedente

14.06

Notizie sul Sentiment di mercato

By Acuity

50%

50%

174 / 360 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Inmode Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 gen 2026, 21:55 UTC

Utili

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 gen 2026, 23:52 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 gen 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 gen 2026, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 gen 2026, 23:40 UTC

Discorsi di Mercato

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 gen 2026, 23:30 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 gen 2026, 23:30 UTC

Discorsi di Mercato

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 gen 2026, 22:37 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 gen 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

22 gen 2026, 21:44 UTC

Utili

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 gen 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 gen 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 gen 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 gen 2026, 21:30 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Capital One To Acquire Brex >COF

22 gen 2026, 21:13 UTC

Utili

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 gen 2026, 21:11 UTC

Utili

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 gen 2026, 21:11 UTC

Utili

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 gen 2026, 21:10 UTC

Utili

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 gen 2026, 21:06 UTC

Utili

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Rev $15.58B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q EPS $3.26 >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net Interest Margin 8.26% >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net $2.13B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Adj EPS $3.86 >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net Charge-Offs $3.8B >COF

22 gen 2026, 21:05 UTC

Utili

Intuitive Surgical 4Q EPS $2.21 >ISRG

Confronto tra pari

Modifica del prezzo

Inmode Ltd Previsione

Obiettivo di Prezzo

By TipRanks

22.73% in crescita

Previsioni per 12 mesi

Media 17.33 USD  22.73%

Alto 21 USD

Basso 15 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Inmode Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

5 ratings

1

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

14.1 / 14.44Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

174 / 360 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Inmode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
help-icon Live chat